MedTrace Logo

Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls

NCT04920526 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2021-06-10

No results posted yet for this study

Summary

In 2013, the Investigators enrolled a cohort of 180 HIV-1 infected adolescent girls and boys ages 9-14 years and administered three doses of the QHPV vaccine (NCT04711265). For this study, the Investigators shall evaluate vaccine effectiveness 9 years post first vaccination.

Participants will be evaluated for HPV type specific antibody, genital HPV infection, genital warts and a subset of 30 participants will be evaluated for memory B and T cell responses.

Conditions

  • HPV-Related Carcinoma

Interventions

DRUG

Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine

No intervention will be administered

Sponsors & Collaborators

Principal Investigators

  • Nelly R. Mugo, MMed Obs Gyn · University of Washington

Eligibility

Min Age
16 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920526 on ClinicalTrials.gov